Posts Tagged ‘pharmaceutical grade fish oil’

Omega-3s intake Linked to Lower Amyloid Levels and reduced risk of Alzheimers

Monday, May 7th, 2012

A study of diet and plasma beta-amyloid in cognitively normal individuals over 65 found that increased consumption of omega-3 fatty acids was significantly associated with lower plasma levels of beta-amyloid protein 42.
Note that none of the other nutrients were found to have a significant association with plasma beta-amyloid.

People who had a lot of omega-3 fatty acids in their diets tended to have lower plasma levels of beta-amyloid proteins, possibly reducing their risk of Alzheimer’s disease, researchers said.

In a cross-sectional study of more than 1,200 cognitively normal individuals older than 65, omega-3 fatty acid intake was significantly predictive of plasma levels of the 40- and 42-residue forms of beta-amyloid protein (AB40 and AB42, respectively), according to Nikolaos Scarmeas, MD, of Columbia University in New York City, and colleagues.

Adjusting for age, education level, and other factors pushed the relationship between AB40 and omega-3 intake into a strong but nonsignificant trend (beta statistic -10.13, P=0.13). But the association with AB42 remained significant, Scarmeas and colleagues reported online in Neurology (beta statistic -7.70, P=0.02).

The same group had previously published results indicating that a Mediterranean-type diet was associated with lower risk of cognitive impairment and Alzheimer’s disease.

Because one of the hallmarks of Alzheimer’s disease is beta-amyloid plaque deposits in the brain, Scarmeas and colleagues sought to determine if dietary factors were related to blood levels of AB40 and AB42.

Their study population was drawn from participants in the Washington Heights/Hamilton Heights Columbia Aging Project in New York City, first recruited in 1992 with a second group enrolled in 1999.

As part of this study, participants completed a detailed diet questionnaire and also provided blood samples. The latter were drawn a mean of 1.2 years after collection of dietary information.

The researchers excluded participants already showing dementia when the dietary questionnaire was administered, since their mental status could affect their self-reporting on diet.

A total of 1,219 participants out of the original 2,778 were included in the current analysis. In addition to 345 with prevalent dementia, another 1,025 could not be included because beta-amyloid levels in plasma weren’t measured.

In addition to omega-3 intake, Scarmeas and colleagues also estimated intake of nine other nutrients: folate, beta-carotene, monounsaturated fats, saturated fats, omega-6 fatty acids, and vitamins C, D, E, and B12.

Only omega-3 intake was significantly associated with plasma AB40 or AB42 levels in any analysis.

The raw data suggested a powerful link:

AB40: beta -24.74, P<0.001

AB42: beta -12.31, P<0.001

But analysis of participant characteristics revealed a number of covariates. Adjusting for age, race-ethnicity, education level, APOE genotype, total caloric intake, and recruitment wave attenuated the relationships noticeably. The beta value for AB40 shrank to -11.96 and the P value increased to 0.06.

The beta value for AB42 also declined, to -7.31, but it remained significant at P=0.02.

Adding adjustments for alcohol drinking and use of certain drugs and nutritional supplements changed the strength of the associations only slightly.

The researchers' conclusion: "The potential beneficial effects of omega-3 [fatty acid] intake on Alzheimer's disease and cognitive function in the literature might be at least partly explained by an AB-related mechanism," they wrote.

Scarmeas and colleagues noted several limitations to the study, including its cross-sectional design and its reliance on a single measurement of plasma AB40 and AB42 levels, which they characterized as "a moving target" during development of cognitive decline.

Also, the researchers relied on participants' self-reports on diet and examined only 10 of many nutrients contained in food.

Finally, Scarmeas and colleagues acknowledged that plasma beta-amyloid proteins do not necessarily reflect amyloid protein levels in the brain.

Omega 3 EPA( Eicosapentaenoic Acid) protects against acid induced colitis

Monday, April 30th, 2012

Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis.
Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN.
Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
Resolvin E1 (RvE1; 5S,12R,18R-trihydroxyeicosapentaenoic acid) is an antiinflammatory lipid mediator derived from omega-3 fatty acid eicosapentaenoic acid (EPA). At the local site of inflammation, aspirin treatment enhances EPA conversion to 18R-oxygenated products, including RvE1, which carry potent antiinflammatory signals. Here, we obtained evidence for reduced leukocyte infiltration in a mouse peritonitis model, where the administration of EPA and aspirin initiated the generation of RvE1 in the exudates. Similar results were obtained with the administration of synthetic RvE1, which blocked leukocyte infiltration. RvE1 also protected against the development of 2,4,6-trinitrobenzene sulfonic acid-induced colitis. The beneficial effect was reflected by increased survival rates, sustained body weight, improvement of histologic scores, reduced serum anti-2,4,6-trinitrobenzene sulfonic acid IgG, decreased leukocyte infiltration, and proinflammatory gene expression, including IL-12 p40, TNF-alpha, and inducible nitric oxide synthase. Thus, the endogenous lipid mediator RvE1 counter-regulates leukocyte-mediated tissue injury and proinflammatory gene expression. These findings show an endogenous mechanism that may underlie the beneficial actions of omega-3 EPA and provide targeted approaches for the treatment of intestinal inflammation

Research shows that omega3 fish oil less than 80% concentrate are not effective at reducing triglyceride levels

Sunday, April 29th, 2012

t research has shown that lower concentrates omega 3 fish oil are not effective especially at reducing triglyceride levels

A study conducted in Europe showed the following that in order for omega3 to be effective in this area it required a concentration of at least 80% and above – none of the products by Nordic Naturals fall into this category or indeed any of those listed on the spreadsheet . The study concluded that “low concentration makes fish oil products impreactical for therapeutic use ”

The study looked at the Omega-3 uptake of three different Omega-3 concentrations:
62% Omega-3 (often sold as ‘Triple Strength’)
80% Omega-3
85% Omega-3
They did not test the regular ‘drug store grade’ fish oil (30% Omega-3) because it was ‘impractical’ to expect anyone to take 10 pills a day.

Every patient in the study took 5,100 mg (5.1 grams) of Omega-3 per day. However the big differentiate was the concentration levels

62% Did Not lower triglycerides

80% Did lower triglycerides

85% Did lower triglycerides

- there is an argument that omega3 at 62% Omega-3 is not pharmaceutical grade , however 80% to 85% are indeed

What was shown when they evaluated the results of the study was the following

There was a significant increase in blood EPA omega3 levels just after 14 days


The concentration levels of EPA were highest in the group taking the 85% concentration – the levels were lower in 62% and 80% group


The were no differences in the levels of DHA omega3 levels across the 3 groups


The most important factor was that the 62% omega3 concentrate did NOT lower triglycerides only the 80% and 85% omega3 fish oil did

RESULT: Even though everyone took the same amount of Omega-3, the chart below shows that 80% and 85% oils were better ‘absorbed.’

This is why it’s critical to take omega3 products such as TakeOmega3 that provide at least 80% Omega-3 concentrations.TakeOmega3 has 990mg omega3 and is an with 85% EPA /DHA concentration
It is very important that most fish oil supplements marketed as pharmaceutical grade or triple strength are only 60% omega 3 concentration

RESULT: Percent change in Triglycerides after taking 62%, 80% and 85% Omega-3 fish oil.

‘Triple Strength’ Fish Oil reduced triglycerides by less than 5% after two weeks. 80% and 85% Omega-3 oils reduced triglycerides by about 20%.
Since the FDA and other agencies does not regulate the terms like ‘pharmaceutical grade,’or ‘Triple Strength,’ anyone can call their product anything they want.However to gain CPP certification a product must fully comply with the conditions as stated by the MHRA – TakeOmega3 offers the highest concentration EPA of any formulation and is certificated by the MHRA

The reason the low concentrates dont work specifically with regards triglyceride reduction is very simple – yes its 62% omega3 but its also almost 40% or one-third non omega3 fats – whereas any oil that is 85% EPA and DHA such as TakeOmega3 will also be 90% in total omega3 as a result there is liitle if any other fatty acids. Omega-3 fats are a poor substrate for synthesis for triglycerides and Omega-3 also inhibit enzyme, acyl CoA:1,2-diacylglycerol acyltransferase due to the natural affinity Omega-3 has for this enzyme.

Harvard Medical School. Charles Serhan, a Harvard Medical School expert on Omega-3:
“The kind of benefits seen in most of the clinical trials with Omega-3 generally have involved much higher doses than you see recommended on supplement labels.”

Wall Street Journal. “Fish-Oil Doses Can Be Hard To Swallow,” David Stipp in Wall Street Journal Special Report, January 8, 2008:
“In trials aimed at lowering triglycerides, patients took three grams of Omega-3 per day. You would have to pop a daily dozen of the typical Omega-3 capsules on the market to get that.”

Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...